Stocks Health care ADCT
NYSE · Health careADC Therapeutics SA (ADCT)
ADC Therapeutics SA brought in $79.6M of revenue over the twelve months to June 30, 2026, up 3.0% from a year earlier. It posted a net loss of $96.9M. In fiscal 2025 capital spending exceeded operating cash flow by $141.4M. At June 30, 2026 it held $219.1M in cash against $6.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What ADC Therapeutics SA does
ADC Therapeutics SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ADCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $81.4M | -$142.6M | -$1.12 | -$141.4M |
| 2024 | $70.8M | -$157.8M | -$1.62 | -$124.7M |
| 2023 | $69.6M | -$240.1M | -$2.94 | -$121.9M |
| 2022 | $209.9M | -$157.1M | -$2.01 | -$139M |
| 2021 | $33.9M | -$230M | n/a | -$236.8M |
| 2020 | $0 | -$246.3M | -$3.77 | -$169.5M |
Latest SEC filings
What ADC Therapeutics SA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 2, 2026
- June 24, 2026
- June 3, 2026
- June 2, 2026
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about ADCT
What does ADC Therapeutics SA do?
ADC Therapeutics SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ADCT.
Is ADC Therapeutics SA profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $96.9M on revenue of $79.6M.
How much revenue does ADC Therapeutics SA make?
Over the twelve months to June 30, 2026 ADC Therapeutics SA reported revenue of $79.6M. That is 3.0% more than a year earlier.
When did ADC Therapeutics SA last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 14, 2026.
Similar companies
Follow ADCT
Get an email when ADC Therapeutics SA files with the SEC: results, executive changes, material agreements and annual reports.
Follow ADCT: get an email when it filesWhere the numbers come from
Financial figures are the values ADC Therapeutics SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.